TG Therapeutics (TGTX) reported $616M in revenue for fiscal 2025, +87.3% year on year. That ranks #2081 by revenue among 2853 SEC filers and #198 in Healthcare. Net income was $447M, a net margin of 72.6%. Revenue has grown 151.7% a year on average since 2016 ($152,000 then). The fiscal 2025 balance sheet shows $1.1B in total assets, $79.1M in cash and $246M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $616M | +87.3% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $123M | +194.1% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $447M | +1,811.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$24.8M | +$15.7M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $214,000 | +375.6% | FY20252025-12-31 |
| Total assetsAssets | $1.1B | +84.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $648M | +191.4% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $79.1M | −56.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $246M | +0.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $205M | $19.8M | Open → |
| Q2 20262026-06-30 | $240M | $7.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- TG Therapeutics, Inc.
- Ticker
- TGTX
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001001316
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Cresco LabsCRLBF | $656M | −$135M |
| NovocureNVCR | $655M | −$136M |
| Axsome TherapeuticsAXSM | $638M | −$183M |
| TG TherapeuticsTGTX | $616M | $447M |
| Cadre HoldingsCDRE | $610M | $44.1M |
| Opko HealthOPK | $607M | −$226M |
| InsmedINSM | $606M | −$1.3B |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=TG Therapeutics — Key figures |url=https://companiesranked.com/en/company/tg-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). TG Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/tg-therapeuticsBibTeX
@misc{companiesranked-en-company-tg-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{TG Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/tg-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001437749-26-006133 · February 27, 2026
{{cite web |title=TG Therapeutics — Key figures — 10-K (0001437749-26-006133) |url=https://www.sec.gov/Archives/edgar/data/1001316/000143774926006133/tgtx20251231_10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.